CD4 and liver cancer: Among gastrointestinal cancers, effects were more heterogeneous; notably, in liver cancer, no significant differences were observed in ORR, DCR, or CD4+/CD8+ ratio between groups, whereas benefits were evident in other digestive malignancies.